Press releases

Three Boston Scientific subsidiaries will pay a total of $16.75 million and admit no liability

Company plans to announce five-year results from the TAXUS II clinical trial

A live webcast and replay of the September 10 conference session will be available

Amendment to provide the Company additional financial flexibility as it implements initiatives designed to increase shareholder value

Transaction would advance company's plan to divest non-strategic assets and strengthen operating and financial performance

BSC to assume sole control of Pain Management business and emerging indications program, Advanced Bionics principals to purchase Auditory business and drug pump program

Endosurgery group to remain wholly owned by Boston Scientific

Business produces a range of products used to manage fluid and measure pressure during angiography and angioplasty procedures

"We made progress in a number of key areas during the quarter," said Jim Tobin, President and Chief Executive Officer

TAXUS PERSEUS clinical program to evaluate platinum enhanced drug-eluting stent